Does Rallies show 13F holders for ENSC?

Yes. Rallies tracks hedge fund and 13F ownership data for ENSC, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ENSC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ENSC. It does not provide personalized investment advice.

ENSC (Ensysce Biosciences, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Ensysce Biosciences, Inc. Common Stock (ENSC) is a publicly traded Healthcare sector company. As of May 21, 2026, ENSC trades at $0.30 with a market cap of $2.94M and a P/E ratio of -0.08. ENSC moved +3.27% today. Year to date, ENSC is -70.19%; over the trailing twelve months it is -87.19%. Its 52-week range spans $0.23 to $14.67. Rallies surfaces ENSC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ENSC stock?

Hedge funds tracked by Rallies that own ENSC include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ensysce Biosciences, Inc. Common Stock.

ENSC Key Metrics

Key financial metrics for ENSC
Metric	Value
Price	$0.30
Market Cap	$2.94M
P/E Ratio	-0.08
EPS	$-3.98
Dividend Yield	0.00%
52-Week High	$14.67
52-Week Low	$0.23
Volume	34.61K
Avg Volume	0
Revenue (TTM)	$5.07M
Net Income	$-10.18M
Gross Margin	0.00%

Top Hedge Funds Holding ENSC

Citadel Advisors holds 23.61K shares of ENSC, changed -72.66% as of Sep 30, 2024.
Renaissance Technologies holds 22.40K shares of ENSC, changed +112.24% as of Sep 30, 2024.

Latest ENSC News

Ensysce Achieves 50% PF614-301 Enrollment, Secures IRB Approval and Expands Patents — May 15, 2026
Ensysce Biosciences Extends MPAR Overdose Protection Patent in Taiwan to 2042 — May 12, 2026
Ensysce Biosciences Closes $2M Convertible Financing with $0.55 Conversion Price — Apr 7, 2026
Ensysce Biosciences Reaches PF614 Phase 3 Enrollment, Breakthrough Designation; Cash at $4.3M — Mar 30, 2026
Ensysce Biosciences Launches Live Q&A Highlighting PF614 Phase 3 Timeline and Commercial Potential — Mar 4, 2026

Recent ENSC Insider Trades

GOWER BOB G bought 90.29K (~$44.09K) on Mar 2, 2023.
GOWER BOB G bought 270.00K (~$128.98K) on Mar 1, 2023.
GOWER BOB G bought 109.30K (~$53.37K) on Feb 28, 2023.

ENSC Analyst Consensus

ENSC analyst coverage data. Average price target: $0.00.

Common questions about ENSC

Who owns ENSC stock?: Hedge funds tracked by Rallies that own ENSC include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ensysce Biosciences, Inc. Common Stock.
Does Rallies show 13F holders for ENSC?: Yes. Rallies tracks hedge fund and 13F ownership data for ENSC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ENSC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ENSC. It does not provide personalized investment advice.